Connect Biopharma (CNTB) Evercore ISI 8th Annual HealthCONx Conference summary

Company overview and product differentiation

• Developing a next-generation IL-4 receptor alpha monoclonal antibody, retimicavir, with rapid onset and unique binding properties, designed for atopic dermatitis and asthma.

• Demonstrates efficacy in both atopic dermatitis and asthma, with a longer dosing interval and a different safety profile compared to Dupixent, notably reducing eosinophil counts.

• Licensed to a major Chinese pharmaceutical company for development in China, with NDA filed for atopic dermatitis and phase 3 asthma study ongoing.

Market opportunity and strategy

• Acute care setting for asthma and COPD identified as a major unmet need, with approximately four million acute episodes annually in the U.S.

• Acute treatment in emergency and urgent care settings seen as a gateway to chronic use, potentially leading to multi-billion dollar commercial opportunity.

• Differentiation from competitors by targeting acute exacerbations, where no other biologics are approved or recommended.

Clinical development and trial design

• Two global phase 2 studies underway for acute asthma and COPD exacerbations, each targeting 160 patients, with data expected in the first half of next year.

• Primary endpoint is treatment failure within 28 days, aiming for a 50% reduction in return visits compared to a 45% control rate.

• Confident in trial powering based on contemporary data, with expectations of rapid onset translating to superior outcomes.

• Interim analysis pending, to be conducted at halfway enrollment.